These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 10634802)

  • 21. Acyl-coenzyme A:cholesterol acyltransferase inhibitors for controlling hypercholesterolemia and atherosclerosis.
    Miyazaki A; Sakai M; Sakamoto Y; Horiuchi S
    Curr Opin Investig Drugs; 2003 Sep; 4(9):1095-9. PubMed ID: 14582454
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Anti-atherosclerotic effect of E5324, an inhibitor of acyl-CoA:cholesterol acyltransferase, in Watanabe heritable hyperlipidemic rabbits.
    Kogushi M; Tanaka H; Ohtsuka I; Yamada T; Kobayashi H; Saeki T; Takada M; Hiyoshi H; Yanagimachi M; Kimura T; Yoshitake S; Saito I
    Atherosclerosis; 1996 Aug; 124(2):203-10. PubMed ID: 8830933
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cardiovascular drugs inhibit MMP-9 activity from human THP-1 macrophages.
    Rival Y; Benéteau N; Chapuis V; Taillandier T; Lestienne F; Dupont-Passelaigue E; Patoiseau JF; Colpaert FC; Junquéro D
    DNA Cell Biol; 2004 May; 23(5):283-92. PubMed ID: 15169608
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inhibitors of acyl-coenzyme a: cholesterol acyltransferase.
    Miyazaki A; Kanome T; Watanabe T
    Curr Drug Targets Cardiovasc Haematol Disord; 2005 Dec; 5(6):463-9. PubMed ID: 16503866
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of the acyl-CoA:cholesterol acyltransferase inhibitor, E5324, on experimental atherosclerosis in rabbits.
    Tanaka H; Ohtsuka I; Kogushi M; Kimura T; Fujimori T; Saeki T; Hayashi K; Kobayashi H; Yamada T; Hiyoshi H
    Atherosclerosis; 1994 Jun; 107(2):187-201. PubMed ID: 7980693
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antiatherosclerotic activity of inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase in cholesterol-fed rabbits: a biochemical and morphological evaluation.
    Bocan TM; Mazur MJ; Mueller SB; Brown EQ; Sliskovic DR; O'Brien PM; Creswell MW; Lee H; Uhlendorf PD; Roth BD
    Atherosclerosis; 1994 Nov; 111(1):127-42. PubMed ID: 7840808
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Preferential pharmacological inhibition of macrophage ACAT increases plaque formation in mouse and rabbit models of atherogenesis.
    Perrey S; Legendre C; Matsuura A; Guffroy C; Binet J; Ohbayashi S; Tanaka T; Ortuno JC; Matsukura T; Laugel T; Padovani P; Bellamy F; Edgar AD
    Atherosclerosis; 2001 Apr; 155(2):359-70. PubMed ID: 11254906
    [TBL] [Abstract][Full Text] [Related]  

  • 28. ACAT inhibitor F-1394 prevents intimal hyperplasia induced by balloon injury in rabbits.
    Aragane K; Fujinami K; Kojima K; Kusunoki J
    J Lipid Res; 2001 Apr; 42(4):480-8. PubMed ID: 11290819
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The relationship between the degree of dietary-induced hypercholesterolemia in the rabbit and atherosclerotic lesion formation.
    Bocan TM; Mueller SB; Mazur MJ; Uhlendorf PD; Brown EQ; Kieft KA
    Atherosclerosis; 1993 Aug; 102(1):9-22. PubMed ID: 8257456
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of FR145237, a novel ACAT inhibitor, on atherogenesis in cholesterol-fed and WHHL rabbits. Evidence for a direct effect on the arterial wall.
    Matsuo M; Ito F; Konto A; Aketa M; Tomoi M; Shimomura K
    Biochim Biophys Acta; 1995 Dec; 1259(3):254-60. PubMed ID: 8541332
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacological properties of R-755, a novel acyl-CoA:cholesterol acyltransferase inhibitor, in cholesterol-fed rats, hamsters and rabbits.
    Matsui Y; Horiuchi K; Yamamoto K; Kanai K
    Jpn J Pharmacol; 2001 Apr; 85(4):423-33. PubMed ID: 11388647
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inhibitors of acyl-CoA:cholesterol O-acyltransferase. synthesis and pharmacological activity of (+/-)-2-dodecyl-alpha-phenyl-N-(2,4,6-trimethoxyphenyl)-2H-tetrazole-5- acetamide and structurally related tetrazole amide derivatives.
    O'Brien PM; Sliskovic DR; Picard JA; Lee HT; Purchase CF; Roth BD; White AD; Anderson M; Mueller SB; Bocan T; Bousley R; Hamelehle KL; Homan R; Lee P; Krause BR; Reindel JF; Stanfield RL; Turluck D
    J Med Chem; 1996 Jun; 39(12):2354-66. PubMed ID: 8691430
    [TBL] [Abstract][Full Text] [Related]  

  • 33. ACAT inhibitor pactimibe sulfate (CS-505) reduces and stabilizes atherosclerotic lesions by cholesterol-lowering and direct effects in apolipoprotein E-deficient mice.
    Terasaka N; Miyazaki A; Kasanuki N; Ito K; Ubukata N; Koieyama T; Kitayama K; Tanimoto T; Maeda N; Inaba T
    Atherosclerosis; 2007 Feb; 190(2):239-47. PubMed ID: 16626720
    [TBL] [Abstract][Full Text] [Related]  

  • 34. NTE-122, an acyl-coa:cholesterol acyltransferase inhibitor, prevents the progression of atherogenesis in cholesterol-fed rabbits.
    Azuma Y; Date K; Ohno K; Matsushiro S; Nobuhara Y; Yamada T
    Jpn J Pharmacol; 2001 May; 86(1):120-3. PubMed ID: 11430463
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Preclinical safety evaluation of avasimibe in beagle dogs: an ACAT inhibitor with minimal adrenal effects.
    Robertson DG; Breider MA; Milad MA
    Toxicol Sci; 2001 Feb; 59(2):324-34. PubMed ID: 11158726
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Avasimibe, an ACAT inhibitor, enhances the lipid lowering effect of atorvastatin in subjects with homozygous familial hypercholesterolemia.
    Raal FJ; Marais AD; Klepack E; Lovalvo J; McLain R; Heinonen T
    Atherosclerosis; 2003 Dec; 171(2):273-9. PubMed ID: 14644397
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Regulation of ACAT activity by a cholesterol substrate pool during the progression and regression phases of atherosclerosis: implications for drug discovery.
    Gillies PJ; Robinson CS; Rathgeb KA
    Atherosclerosis; 1990 Aug; 83(2-3):177-85. PubMed ID: 2242095
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antiatherosclerotic effects of antioxidants are lesion-specific when evaluated in hypercholesterolemic New Zealand white rabbits.
    Bocan TM; Mueller SB; Brown EQ; Uhlendorf PD; Mazur MJ; Newton RS
    Exp Mol Pathol; 1992 Aug; 57(1):70-83. PubMed ID: 1397193
    [TBL] [Abstract][Full Text] [Related]  

  • 39. HL-004, the ACAT inhibitor, prevents the progression of atherosclerosis in cholesterol-fed rabbits.
    Asami Y; Yamagishi I; Murakami S; Araki H; Tsuchida K; Higuchi S
    Life Sci; 1998; 62(12):1055-63. PubMed ID: 9519807
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Heterocyclic amides: inhibitors of acyl-CoA:cholesterol O-acyl transferase with hypocholesterolemic activity in several species and antiatherosclerotic activity in the rabbit.
    White AD; Purchase CF; Picard JA; Anderson MK; Mueller SB; Bocan TM; Bousley RF; Hamelehle KL; Krause BR; Lee P; Stanfield RL; Reindel JF
    J Med Chem; 1996 Sep; 39(20):3908-19. PubMed ID: 8831757
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.